Sifi and Faes Farma: Revolution in ophthalmology is imminent!

Sifi and Faes Farma: Revolution in ophthalmology is imminent!

Aci S. Antonio, Italien - On June 10, 2025, the international company Sifi, which specializes in ophthalmology, announced that he signed an agreement to sell 100 % of its shares to Faes Farma. OTS Strong commercial synergies are to be created that support the financing of the further development of the SIFI portfolio, in particular from Akantior in the USA. Faes Farma is a leading pharmaceutical company listed on the Spanish stock exchange and expected to benefit significantly from the integration of Sifi and Laboratorios Edol, which was recently taken over.

Ophthalmology is identified as a central area for the combined company. Around 20 % of the Pro-Forma income of this merged company is eliminated on this division. Sifi plans to further expand its existing infrastructure, including the production facilities in ACI S. Antonio, to optimize international access to his portfolio.

strategic importance of fusion

A decisive advantage of the merger is to open up new markets in Europe, including Italy, France, Romania and Turkey. The product integration is intended to create cross-selling opportunities and increase operational efficiency. Sifi will continue to invest in the development of Akantior (PoliHexanide 0.08 %), which is the world's first and only approved therapy for acanthamoeba keratitis (AK).

The market launch of Akantior in Germany is planned for October 2024, while clinical development for the treatment of fungal ceratitis is scheduled to begin soon. The transaction evaluates Sifi with a preliminary company value that corresponds to a double -digit multiple of the EBITDA from 2024. The end of the transaction is expected in the third quarter of 2025, subject to the necessary permits by the competition authorities and the shareholder assembly of Faes Farma.

growth in the Orphan Drugs area

The newly founded unit will also benefit from the growing importance of the market for Orphan Drug. According to Imarc Group , the global market for Orphan Drugs in 2024 was estimated at $ 237.30 billion and is expected to grow to 582.54 billion to 2033 with an annual growth rate of 2025 to 2033. This market is driven by increasing awareness of rare diseases, technological progress and favorable regulatory framework.

2024 lived an estimated 300 million people worldwide with rare diseases. Around 30 million people are only affected in the United States. The FDA has recently given Orphan Drug Status for several new medication, including Rilzabrutinib for two rare diseases. These developments illustrate the enormous market potential and the need for effective therapies.

Sifi, founded in 1935, exported to over 60 countries. Faes Farma brings more than 90 years of experience and works in over 130 countries. Evercore Partners and Mediobanca are the exclusive financial advisors for SIFI's shareholders, while J.P. Morgan SE acts as a financial advisor and external financier from Faes Farma.